Thrombomodulin, Human, mAb RTM96

Catalog #: HM2146
Quantity: 100 µg

Original supplier of innate immunity products since 1994.

Our commitment to quality: Read more!

Contact our support team for more product information.

Can't find your application for a product? Request a sample!

Monoclonal antibody RTM96 recognizes thrombomodulin (a C-type lectin also known as CD141), a complex molecule located on the endothelium and a key feature in the protein C pathway. The protein C anticoagulant pathway serves as a major system for controlling coagulation and limiting inflammatory responses, and potentially decreasing endothelial cell apoptosis in response to inflammatory cytokines and ischemia. The essential components of the pathway involve thrombin, thrombomodulin, the endothelial cell protein C receptor (EPCR), protein C and protein S. Thrombomodulin binds thrombin, directly inhibiting its clotting and cell activation potential while at the same time augmenting protein C. The endothelial cell protein C receptor (EPCR) augments protein C activation by the thrombin-TM complex more than 10-fold. TM also accelerates thrombin activation of a plasma procarboxypeptidase B, named thrombin activatable fibrinolysis inhibitor or TAFI resulting in slowing clot lysis. The inhibited thrombin rapidly dissociates from thrombomodulin, regenerating the anticoagulant surface. Thrombomodulin also has direct anti-inflammatory activity, minimizing cytokine formation in the endothelium and decreasing leukocyte-endothelial cell adhesion. Thrombomodulin inhibits leukocyte binding to activated endothelium. TM has been detected in a variety of cells and tissues in adults and during development, including astrocytes in the brain, keratinocytes, endothelial cells, mesothelial cells of the peritoneum, and circulating neutrophils, monocytes, and platelets. During fetal development, TM plays a central role in controlling the growth and survival of trophoblast cells in the placenta, a function essential for the maintenance of pregnancy. Thrombin binding to thrombomodulin involves anion binding exosite 1 on thrombin and epidermal growth factor (EGF) domains 4 to 6 on thrombomodulin. The monoclonal antibody RTM96 reacts with the EGF4 domain, thereby inhibiting the biological activity of thrombomodulin.


Catalog number HM2146
Product type Monoclonal antibodies
Quantity 100 µg
Formulation 1 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin.
Isotype Rat IgG2a
Species Human
Storage and stability Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
Precautions For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use of or derivation of this product.
Disease Cardiology and metabolism
  • Application:
    FC, FS, W
  • Use:
    For flow cytometry and Western blotting dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10. For inhibition of biological activity in vitro dilutions have to be made according to the amount of thrombomodulin to be inactivated.
1. Domotor, E et al; Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood 2003, 101: 4797
2. Sturn, D et al; Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003, 102: 1499
3. Charles, T et al; The protein C pathway. Chest 2003, 124: 26S
4. Wouwer, M van de et al; Novel functions of thrombomodulin in inflammation. Crit Care Med 2004, 5: 254.